secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2026-09-08T12:34:27+00:00
Accession:  0001759425-26-000047
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Mirum names Rob Myers CMO; Joanne Quan exits with severance
-----------------------------------------------------------

- Rob Myers, M.D. appointed Chief Medical Officer, effective Sept 21, 2026, succeeding Joanne Quan, M.D.
- Joanne Quan ceased as CMO Sept 2, 2026; employment termination expected Oct 19, 2026.
- Separation agreement: vested stock option exercise period extended to 12 months post-separation; 2026 annual bonus paid at 100% target.
- Benefits contingent on customary conditions; separation qualifies as involuntary under Severance Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000175942526000047/0001759425-26-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000175942526000047/mirm-20260902.htm
  HTML page:      https://secwatch.observer/filing/0001759425-26-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer